Morgan Stanley raised the firm’s price target on iRhythm (IRTC) to $205 from $195 and keeps an Overweight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm presents new data on Zio long-term continuous ECG monitoring
- Confident Buy Rating for Irhythm Technologies Amidst LCD Concerns and Market Expansion Opportunities
- Confident Outlook for Irhythm Technologies Amid Proposed Medicare Policy Changes
- iRhythm falls -8.5%
- Favorable Outlook for Irhythm Technologies Amid Regulatory Challenges and Strong Sales Projections